Fresenius Medical Care and CCINSHAE Partner to Expand Kidney Treatment Access in Mexico

Fresenius Medical Care and CCINSHAE's Strategic Collaboration to Expand Innovative Therapy

Image Credits: Fresenius Medical Care

Announcement

Fresenius Medical Care, a global provider of products and services for patients suffering from renal diseases, will expand high-volume hemodiafiltration (high-volume HDF) availability for patients in Mexico. The access will cover seven centers out of ten. The partnership with Mexico’s coordination of national institutes of health and specialty hospitals (CCINSHAE) will support the pilot program. The program will provide access to hemodialysis therapies to low-income patients (with no medical coverage). The thought and efforts have fueled the healthcare market.

Contract

CCINSHAE and Fresenius Medical Care have entered a two-year contract that includes the participation of Fresenius Medical Care 5008S CorDiax technology in renal treatment centers covering Mexico’s metropolitan area and CCINSHAE centers in Mexico City, with 150 system installations. The technology highly supports high-volume HDF and standard hemodialysis, a therapy that will contribute to patients’ improvement with low cost in the healthcare system.

The collaboration between these two respective companies and institutes has recently enabled HighvolumeHDF treatment for new CCINSHAE 240 patients. These patients don’t have any access to any private or public medical coverage. Around 410 regular patients have started receiving a treatment of HighvolumeHDF since last year.

Few patients were encountered as part of the hemodialysis program in CCINSHAE centers, and others were new patients who separately registered with the CCINSHAE center for various reasons. The program witnessed several patients through various sources, which made this program more effective and required for every individual.

HighVolumeHDF

High-volume Hemodiafiltration is bolstered by various clinical studies consisting of randomized, controlled, and international ‘convince trial’. This trial is a comparison between standard high-flux hemodialysis and high-volume hemodiafiltration. The study projected a 23% of less rate on average patients with the treatment of high-volume hemodiafiltration. It is less in comparison to the standard treatment of high-flux hemodialysis.

Fresenius Medical Care’s HighVolume HDF therapy is adopted (accepted) in Canada, Argentina, Ecuador, Uruguay, Peru, Brazil, Chile, Mexico, Caribbean islands, Colombia, and Panama.

Additionally, the Company is planning to introduce HighVolumeHDF therapy in Asia Pacific, Europe, and Latin America.

Progress

In February 2024, Fresenius Medical Care became the first ever company to receive US FDA approval for the 5008X Hemodialysis system. This year, in May 2025, received FDA 510 (K) approval for the advanced version and additional features of the new hemodiafiltration-capable 5008X CARE system.

The overall progress encourages the company to pave the way to introduce innovation to the healthcare sector.